Andere Sprachen Cullinan Therapeutics, Inc.

Aktien

A2QL3C

US2300311063

CGEM

Markt geschlossen - Nasdaq Andere Börsenplätze 22:15:00 03.05.2024			% 5 Tage	% 1. Jan.
28,35 ^USD	+2,79 %		+12,06 %	+178,21 %

29.04.	Cullinan Therapeutics ernennt Mary Kay Fenton zum CFO	MT
16.04.	Transcript : Cullinan Oncology, Inc. - Special Call

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Cullinan Therapeutics Appoints Mary Kay Fenton as CFO	29.04.
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer	29.04.
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer	29.04.
Cullinan Therapeutics, Inc Appoints Mary Kay Fenton as Chief Financial Officer	29.04.
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024	24.04.
Cullinan Oncology : Therapeutics Corporate Update	16.04.
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases	16.04.
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases	16.04.
Cullinan Oncology, Inc. Announces Important Updates About Its Plan to Expand into Autoimmune Diseases, the Scientific Rationale for Developing CLN-978 in Autoimmune Diseases	16.04.
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement	16.04.
Cullinan Oncology, Inc. announced that it expects to receive $280.000024 million in funding from a group of investors	15.04.
Cullinan Oncology, Inc.(NasdaqGS:CGEM) added to S&P Biotechnology Select Industry Index	18.03.
Cullinan Oncology Finance Chief Jeffrey Trigilio to Leave	14.03.
Cullinan Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14.03.
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results	14.03.
Cullinan Oncology, Inc. Announces Resignation of Jeff Trigilio as Chief Financial Officer , Effective from March 29, 2024	14.03.
Cullinan Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14.03.
North American Morning Briefing : Stock Futures -2-	13.03.
Cullinan Oncology Secures FDA Approval for CLN-619's Investigational New Drug Application in Multiple Myeloma	01.03.
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma	01.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Cullinan Therapeutics, Inc.

Aktien

A2QL3C

US2300311063

CGEM

Andere Sprachen

Filter